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Regarding impact of epoetin
alfa on clinical end points in
patients with chronic renal
failure: A meta-analysis
To the Editor: We read the recent article by Jones
et al [1] with interest. This meta-analysis purports to show
that recombinant human erythropoietin (rHuEPO) ther-
apy increases hemoglobin levels and reduces hospital-
ization rates. Unfortunately, the design of this study has
several potential limitations that were not expressed in
the manuscript.
First, the inclusion criteria were so exclusive that sev-
eral relevant trials were not included, which may have
influenced the outcome of the meta-analysis. It is note-
worthy that these criteria excluded the three largest and
most recent randomized studies. An example of an ex-
cluded study that might have altered the pooled effect of
rHuEPO therapy is the work by Besarab et al [2].
Second (and more important), 11 of 16 trials included
were nonrandomized. Because nonrandomized studies
are more likely to exaggerate estimates of treatment ef-
fect [3, 4], and because inclusion of lower quality studies is
known to affect the results of meta-analyses [5], we urge
that the reader be circumspect of results driven by these
11 trials alone. Because the excluded trials tended to find
no benefit of rHuEPO with respect to hospitalization, we
wonder what the meta-analysis would have shown if all
available randomized trials were considered.
In addition to these considerations about study de-
sign, we disagree with the authors’ interpretation of the
data. The authors state that “strong evidence” shows
that rHuEPO reduces hospitalization rates, and by ex-
tension, healthcare costs. However, hospitalization costs
are determined primarily by the number of hospital days,
rather than by the total number of hospitalizations. While
Jones et al state that the length of stay was reduced
with rHuEPO therapy, its “benefit” was not statistically
significant.
Although erythropoietic therapy undoubtedly raises
hemoglobin levels and probably improves quality of life,
the available data do not convincingly indicate that it re-
duces hospitalization rates in people with kidney disease.
Rather, we view the information as weak and inconsis-
tent.
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Editor’s note: The study by Jones et al was sponsored
by RW Johnson Pharmaceutical Research and Develop-
ment (Raritan, NJ), a subsidiary of Johnson and John-
son, which operates companies that manufacture epoetin
alfa.
Reply from the Authors
The letter from Tonelli et al [1] concerning our work
reveals what we consider to be a number of misunder-
standings and inconsistencies, which we would like to
address.
The work is criticized as being too exclusive (i.e., omit-
ting Besarab et al [2]), and at the same time, too inclusive
in that it included studies other than randomized con-
trolled trials (RCTs). Besarab et al [2] is actually a study
of congestive heart failure patients on dialysis, and not
directly relevant to our focus on chronic renal failure pa-
tients. Within this population, we sought to include all
evidence available.
We must, however, strenuously reject the assertion
from the letter’s first paragraph “. . . potential limitations
that were not expressed in the manuscript.” The use of
non-RCTs, as well as the strengths and weaknesses of
the accumulated data, are all well documented in the
manuscript.
We agree the impact of research design is a criti-
cally important issue. However, perhaps it was not im-
mediately clear that Table 5 reanalyzes the data from
RCTs alone. In contrast to the assertion by Tonelli
et al, the estimates of effect from the RCT’s are simi-
lar to, or slightly larger than, those from all studies as a
whole.
